In rural Parasia, Madhya Pradesh, a simple bottle of cough syrup became a death sentence. Three-year-old Mayank Suryavanshi developed a fever in late September. His parents did what any responsible family would do, they visited a local doctor, received a prescription for Coldrif cough syrup, and followed the instructions carefully. Within days, his condition deteriorated beyond recovery. On October 9, Mayank died of acute kidney failure. He was one of at least 24 children killed by locally produced medicine containing nearly 500 times the permissible level of diethylene glycol, a toxic industrial chemical. His father’s plea, “My child should be the last,” has pushed India’s government into long delayed action.

Breakdown

Context:
India’s pharmaceutical sector, often hailed as the pharmacy of the world, is worth over 50 billion dollars and includes more than 10,000 manufacturing units. While global giants dominate exports, nearly 40 percent of production comes from small and medium enterprises operating with minimal oversight. It is within this fragmented tier that safety failures have proved fatal.

This is not India’s first pharmaceutical disaster. In 2022 and 2023, Indian made cough syrups were linked to the deaths of over 140 children across Africa and Central Asia. The global backlash led New Delhi to mandate World Health Organization compliant manufacturing upgrades by mid 2024. Large firms met the target. Smaller manufacturers were given until December 2024, a delay that proved deadly.

The Latest Tragedy:
The contaminated Coldrif cough syrup was produced by Sresan Pharmaceutical, a small Chennai based company. Tests revealed diethylene glycol contamination at 48.6 percent, nearly 500 times above permissible limits. The chemical, used in antifreeze and brake fluid, causes acute kidney failure when ingested. Investigators found Sresan’s facility to be a shed-like structure riddled with safety violations. It has since been shut, its license revoked, and its founder arrested. But the syrup had already reached pharmacies and households.

The Regulatory Failure:
The tragedy exposed India’s two tier safety regime. Since 2023, cough syrups meant for export have required government lab testing, but no such rule applied to domestic sales. Indian children were left less protected than foreign ones. The government’s latest move, refusing further compliance extensions, marks a turning point. Regulators have confirmed that all manufacturers must meet WHO standards by December 2024, without exception. Officials also announced that all oral liquid drugs must now be tested for diethylene glycol and ethylene glycol before release, a step that should have been standard decades ago.

Human Cost:
In Parasia, grief has turned into rage. Parents who trusted local doctors and pharmacies are left shattered. “The medicine turned into poison and killed my daughter,” said school teacher Sushant Thakre, who lost his two-year-old child. Investigators are now collecting samples across the region, suspending pharmacies, and urging families to surrender remaining bottles of the syrup.

The Larger Pattern:
India’s regulatory system has long tolerated low compliance among small drugmakers. Despite multiple deaths abroad, few faced punishment before now. Cost cutting, poor oversight, and lax enforcement allowed substandard drugs to persist. The Parasia tragedy has forced a reckoning.

What’s Next:
The government has made clear that no more extensions will be granted. Smaller manufacturers must upgrade to WHO standards or exit the market. Regulators argue that large firms can cover supply shortages. The goal is not to test every batch but to ensure quality from the start. India’s move from post production testing to process based compliance marks a major shift in its pharmaceutical regulation philosophy.

Why This Matters

This is more than a compliance issue, it is a moral one. When parents give a prescribed medicine to a sick child, they are trusting a system that must never fail. In Parasia, that system collapsed completely. The double standard that gave exported drugs higher scrutiny than domestic ones shows how profit and reputation took precedence over protection. The tragedy has now forced India to confront its own negligence.

India’s credibility as a global drug supplier depends entirely on restoring trust. Every contamination incident weakens the brand that took decades to build and strengthens competitors in China and Bangladesh. The economic cost of enforcing WHO standards pales beside the reputational and human cost of inaction.

The Big Picture

India’s pharmaceutical crisis reflects a deeper struggle faced by fast growing economies, how to balance scale with safety. The parallels with China’s food scandals or Bangladesh’s factory disasters are clear. Growth has outpaced governance, and quality control systems have not kept up.

Unlike most industrial failures, pharmaceutical lapses kill swiftly and indiscriminately. This makes drug safety not just a regulatory requirement but a public health imperative. If India successfully enforces WHO standards across its 10,000 plus facilities, it will set a global example for balancing affordability with accountability. If it fails, it will confirm critics’ fears that rapid Industrialization without rigorous oversight endangers lives both at home and abroad.

The Crunch

Twenty four children are dead because a manufacturer ignored safety standards, regulators granted extensions, and the government enforced rules selectively. The promise of reform now rings hollow unless followed by visible, sustained enforcement. India has issued deadlines before, only to retreat under industry pressure. This time, the system must hold.

Accountability must extend beyond small operators to all levels of the supply chain. Drug inspectors need resources, penalties must be severe, and violations must be publicly reported. For the families of Parasia, reform will come too late. But their loss has forced India to confront a truth it can no longer ignore, safety is not negotiable, and children should never pay for regulatory failure with their lives.